More than one in 10 Americans today are living with diabetes (1). To prevent acute and chronic complications of diabetes, including death, patients with diabetes often require multiple medications and medication management supplies to enable effective, safe, and evidence-based control of hyperglycemia. These include insulin and noninsulin medications, technologies for glucose monitoring, and equipment for administration of injectable medications (both insulin and noninsulin injectables).

Management of hyperglycemia is increasingly expensive for patients and the health care system, having increased 240% from the period 2005–2007 to 2015–2017, from $16.9 billion to $57.6 billion annually (2). Although the majority of these costs are borne by public and private payers (2), patients and caregivers increasingly report cost-related distress, nonadherence, and adverse health outcomes stemming from the costs of managing their disease (3–5). It is therefore vital for primary care clinicians, who care for...

You do not currently have access to this content.